Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
65.94
+2.79 (+4.43%)
Streaming Delayed Price
Updated: 9:46 AM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Got $1,000? Check Out These 3 Top Biotech Stocks
December 03, 2021
Two big biotechs and one smaller one that could be winners over the long term.
Via
The Motley Fool
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
November 29, 2021
Smaller companies are working on next-generation approaches to Covid treatment.
Via
Investor's Business Daily
Why Are NRx Pharma's Shares Soaring Premarket?
November 29, 2021
NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's...
Via
Benzinga
3 Dividend Stocks That Are Dirt Cheap Right Now
November 25, 2021
If you want dividend growth, dividend safety, and an undervalued stock, these three fit the bill.
Via
The Motley Fool
This Cheap Stock Is Paying An Unusually High Yield
November 01, 2021
Gilead has increased their dividend for seven consecutive years. The three-year dividend growth rate of 9.4% shows the level of growth they’re capable of delivering.
Via
Talk Markets
A Look Into Gilead Sciences Debt
November 24, 2021
Shares of Gilead Sciences (NASDAQ:GILD) fell by 1.76% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences...
Via
Benzinga
Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial
November 24, 2021
Gilead Sciences Inc (NASDAQ: GILD) and Merck & Co Inc (NYSE: MRK) have temporarily paused enrollment in the Phase 2 study evaluating the combination...
Via
Benzinga
Gilead's Trodelvy Approved In Europe For Aggressive Form Of Breast Cancer
November 23, 2021
The European Commission has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan) as monotherapy for triple-negative breast cancer (...
Via
Benzinga
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...
Via
Benzinga
Exposures
COVID-19
Product Safety
Next Week Trading Opportunities - GILD, ETSY, FCEL, PLUG, SNOW, AAPL
November 21, 2021
With the assistance of AI we can identify patterns, trends, and buy/sell signals. Here are the prospects in the coming week for these six stocks.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
1 Cancer Stock on Buyout Watch in 2022
November 21, 2021
Cardiff Oncology is a prime takeover target heading into 2022.
Via
The Motley Fool
Exposures
COVID-19
Dividend Initiators: A Fertile Ground For Research
November 19, 2021
Only a company with a certain type of business can afford to grow dividends over a full business cycle.
Via
Talk Markets
Gilead Files US Application For Bulevirtide In Severe Form Of Viral Hepatitis
November 19, 2021
Gilead Sciences Inc (NASDAQ: GILD) has submitted a marketing application to FDA for bulevirtide for injection (2 mg) for chronic hepatitis delta virus (HDV)...
Via
Benzinga
Exposures
Product Safety
Arcus Stock Rockets To Record As Gilead Unexpectedly Opts Into Cancer Drugs
November 18, 2021
Gilead opted into three programs from a small biotech company, sending shares flying.
Via
Investor's Business Daily
Why Are Arcus Biosciences Shares Trading Higher Today?
November 18, 2021
Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT...
Via
Benzinga
Why Arcus Biosciences Stock Is On Fire Today
November 18, 2021
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.
Via
The Motley Fool
2 High-Yield Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash
November 15, 2021
AbbVie and Gilead Sciences are two top high-yield stocks that could save your portfolio in the event of a marketwide downturn.
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
On Target: This Company Says It Delivers Drugs Exactly How You Need Them
November 15, 2021
Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
November 12, 2021
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products.
Via
Talk Markets
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...
Via
Benzinga
Top 5 Stocks To Buy In November 2021
November 09, 2021
High-quality dividend growth stocks are some of the very best stocks in the whole world. They represent equity in world-class businesses that pay reliable, rising dividends.
Via
Talk Markets
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
November 06, 2021
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...
Via
Talk Markets
Best and Worst Performers Since the COVID Crash Low
November 05, 2021
The major indices have consistently been hitting new record highs over the past few days with the S&P 500 having now more than doubled off the COVID Crash low on March 23, 2020.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
November 05, 2021
Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high,...
Via
Benzinga
Exposures
COVID-19
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Exposures
COVID-19
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
November 05, 2021
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
November 05, 2021
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing...
Via
Benzinga
Exposures
COVID-19
Product Safety
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
November 02, 2021
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...
Via
Benzinga
Healthcare Stocks Subject to Government Policy
November 02, 2021
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
5 M&A Stocks to Watch as Goldman Calls for a Big Jump in Deals
November 01, 2021
Goldman Sachs predicts the Democrats' new tax plan could yield positive results for M&A-focused companies. Here are the M&A stocks to watch.
Via
InvestorPlace
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.